Prostate cancer
480 results
101 - 200
PREDICT Prostate online risk score accurately predicts the prognosis for men with nonmetastatic prostate cancer
Prostate cancer - PSA screening for prostate cancer not recommended (USPSTF)
- Better estimate of prostate cancer risk based on the number of close relatives with prostate cancer and their age at diagnosis
- Vitamin E supplementation increases risk of prostate cancer
- Five-alpha-reductase inhibitors for prostate cancer prevention
5‐alpha‐reductase inhibitors for prostate cancer prevention- PSA test in prostate cancer screening
- Radical prostatectomy versus deferred treatment for localised prostate cancer
- Maximal androgen blockade for advanced prostate cancer: Cochrane systematic review
- Increased vegetable consumption does not decrease prostate cancer progression
- Quality of life varies after different prostate cancer treatments
- Ask-tell-ask approach to discussing prostate cancer screening
- Prostate cancer screening increases harm risk without decreasing mortality
- Hormones + radiation decrease mortality compared with radiation in prostate cancer
- Approximately 12% of men regret prostate cancer treatment decisions (HCaP-NC)
- Radical prostatectomy versus watchful waiting for newly diagnosed prostate cancer
- Have the USPSTF recommendations against screening caused more aggressive prostate cancer?
- Observation = radical prostatectomy for most pts with localized prostate cancer (PIVOT)
- The full truth about prostate cancer screening is suppressed again (ERSPC)
- Bisphosphonates for advanced prostate cancer
- Dutasteride slows progression in men with low-grade prostate cancer (REDEEM)
- Psychosocial interventions for men with prostate cancer: Cochrane systematic review
- Men with localized prostate cancer have inaccurate perceptions of their prognosis
- Prostate MRI, with or without MRI‐targeted biopsy, and systematic biopsy for detecting prostate cancer
- MA: Low-quality evidence finds DRE screening for prostate cancer inaccurate
- Adjuvant radiotherapy following radical prostatectomy for prostate cancer
- Prostate cancer screening: no mortality benefit after 15 years of follow-up (PLCO)
- Prostate cancer screening: no mortality benefit after 13 years of follow-up (PLCO)
- Dose‐escalated radiotherapy for clinically localized and locally advanced prostate cancer
- Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer
- Sexual, urinary, and bowel dysfunction common after treatment for localized prostate cancer